Search clinical trials for: RSVPreF3 OA investigational vaccine

Total 109 results

GlaxoSmithKline

Completed

A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

United States, Canada, Sweden
GlaxoSmithKline

Recruiting

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above

Respiratory Syncytial Virus Infections

United States, Canada, Japan, Germany, Australia, South Africa
GlaxoSmithKline

Active, not recruiting

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above (RSV OA=ADJ-023)

Respiratory Syncytial Virus Infections

Spain, Japan, Italy, United States, Australia, Canada, Korea, Republic of, Germany
GlaxoSmithKline

Active, not recruiting

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

United States, Finland, Germany, Japan, Taiwan
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above

Respiratory Syncytial Virus Infections

Argentina, United States, Germany, Spain, Poland, Canada, Japan, Netherlands
GlaxoSmithKline

Completed

Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

Respiratory Syncytial Virus Infections

United States, Belgium
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

Panama, New Zealand, South Africa
GlaxoSmithKline

Recruiting

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

Respiratory Syncytial Virus Infections

United States, Belgium, Netherlands, Spain
GlaxoSmithKline

Active, not recruiting

Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults

Respiratory Syncytial Virus Infections

Spain, United States, Belgium, Poland
GlaxoSmithKline

Active, not recruiting

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

United States, Canada, Spain, Finland, Germany, Japan, Estonia, Belgium, South Africa, Korea, Republic of, Italy, Russian Federation, Australia, Mexico, United Kingdom, New Zealand, Poland
GlaxoSmithKline

Active, not recruiting

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults (RSV-OA=ADJ-020)

Respiratory Syncytial Virus Infections | Respiratory Syncytial Viruses

United States, Canada
GlaxoSmithKline

Completed

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above

Respiratory Syncytial Virus Infections

France, Finland, Belgium, Spain, United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults

Infections, Staphylococcal

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Tetanus Immunisation (Healthy Volunteers) | Diphtheria Immunisation (Healthy Volunteers) | Pertussis Immunisation (Healthy Volunteers)

Canada
GlaxoSmithKline

Active, not recruiting

Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.

Sexually Transmitted Diseases

United States, Germany, Philippines, France, Spain, South Africa, United Kingdom, Brazil
GlaxoSmithKline

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

Influenza

United States
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Completed

Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine

Prevention of Influenza

China
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

Influenza

United States, Canada
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Belgium
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults

Influenza

Germany
GlaxoSmithKline

Recruiting

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

Respiratory Syncytial Virus Infections

United States, Australia, Italy, Spain, Belgium, Korea, Republic of, France, Canada, Finland, Taiwan, Thailand, Brazil, India, New Zealand, Germany, South Africa, Colombia, Panama, Philippines, Argentina, Bangladesh, Dominican Republic and more
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

Influenza

United States, Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

Influenza

United States, Canada
GlaxoSmithKline

Withdrawn

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age

Influenza
International AIDS Vaccine Initiative
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines

HIV Infections

Kenya, Zambia, Uganda
Institut Pasteur

Completed

Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine

HIV

Belgium
Pfizer

Completed

Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age

Respiratory Syncytial Virus

Australia
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd.; Jiangsu Province Center for...

Active, not recruiting

A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age

Varicella

China
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

Influenza | SARS-CoV-2

United States
Meissa Vaccines, Inc.

Completed

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Completed

A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.

Respiratory Syncytial Virus Infections

Finland, Spain, Canada, United States, Korea, Republic of
GlaxoSmithKline

Completed

Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years

Influenza

Slovakia, Estonia
GlaxoSmithKline

Active, not recruiting

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

Measles; Mumps; Rubella; Chickenpox

United States, Taiwan, Spain, Argentina, Turkey, Colombia, Puerto Rico, Latvia, Chile
Sinovac Biotech Co., Ltd

Completed

Clinical Trial of Recombinant Hepatitis B Vaccine (Hansenula Polymorpha, 10μg)

Hepatitis B

China
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly

Influenza

Estonia, Slovakia
GlaxoSmithKline
IQVIA, USA

Active, not recruiting

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Chickenpox

Taiwan, Poland, United States, Estonia, Puerto Rico, Mexico
Janssen Vaccines & Prevention B.V.

Completed

A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older

Influenza, Human Prevention | Respiratory Syncytial Viruses Prevention

United States
Pfizer

Recruiting

A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants (MORISOT)

Respiratory Syncytial Virus

South Africa
GlaxoSmithKline

Completed

Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age

Influenza

Thailand, Australia, Mexico, Costa Rica, Philippines, Colombia, Singapore, Brazil
Meissa Vaccines, Inc.

Recruiting

Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

Respiratory Syncytial Virus (RSV)

United States
GlaxoSmithKline

Completed

A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults

Respiratory Syncytial Virus Infections

Japan
Sinovac (Dalian) Vaccine Technology Co., Ltd.

Completed

A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines

Varicella

China
National Institute of Allergy and Infectious Diseases...

Completed

Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine

Dengue Virus

United States
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes

Influenza

Germany
Sinovac Life Sciences Co., Ltd.

Recruiting

Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population

Tetanus

China
Janssen Vaccines & Prevention B.V.

Completed

A Study Evaluating the Immunogenicity of Different Clinical Trial Materials of Ad26.RSV.preF- Based Vaccine in Adults Aged 60 - 75 Years Old

Respiratory Syncytial Virus Prevention

United States
GlaxoSmithKline

Completed

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

Influenza

United States
Sinovac Research and Development Co., Ltd.

Completed

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants

Mumps

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of Quadrivalent Influenza Vaccine Among Adults

Influenza

United States

3

Subscribe